IL186699A0 - Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes - Google Patents
Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomesInfo
- Publication number
- IL186699A0 IL186699A0 IL186699A IL18669907A IL186699A0 IL 186699 A0 IL186699 A0 IL 186699A0 IL 186699 A IL186699 A IL 186699A IL 18669907 A IL18669907 A IL 18669907A IL 186699 A0 IL186699 A0 IL 186699A0
- Authority
- IL
- Israel
- Prior art keywords
- liposomes
- ovarian cancer
- advanced ovarian
- treating advanced
- doxorubicin entrapped
- Prior art date
Links
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 title 2
- 206010033128 Ovarian cancer Diseases 0.000 title 1
- 206010061535 Ovarian neoplasm Diseases 0.000 title 1
- 229960004679 doxorubicin Drugs 0.000 title 1
- 239000002502 liposome Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67418805P | 2005-04-21 | 2005-04-21 | |
| PCT/US2006/015528 WO2006116341A1 (en) | 2005-04-21 | 2006-04-20 | Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL186699A0 true IL186699A0 (en) | 2008-02-09 |
Family
ID=36811891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL186699A IL186699A0 (en) | 2005-04-21 | 2007-10-16 | Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20070026060A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1874324A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2008538584A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20080008367A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101163485A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006238877A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0609939A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2605669A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL186699A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007013056A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006116341A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2704303T3 (es) | 2010-08-24 | 2019-03-15 | Dana Farber Cancer Inst Inc | Procedimientos para la predicción de una respuesta contra el cáncer |
| ES2768344T3 (es) | 2011-06-17 | 2020-06-22 | Myriad Genetics Inc | Métodos y materiales para evaluar el desequilibrio alélico |
| UY34295A (es) * | 2011-09-08 | 2013-04-30 | Servier Lab | Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida |
| JP6325453B2 (ja) | 2011-12-21 | 2018-05-16 | ミリアド・ジェネティックス・インコーポレイテッド | ヘテロ接合性の消失（ｌｏｓｓｏｆｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 |
| ES2687024T3 (es) | 2012-02-23 | 2018-10-23 | Children's Medical Center Corporation | Procedimientos para predecir la respuesta contra el cáncer |
| CA2867434C (en) | 2012-06-07 | 2021-10-12 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| US10308986B2 (en) | 2013-03-14 | 2019-06-04 | Children's Medical Center Corporation | Cancer diagnosis, treatment selection and treatment |
| CA2931181C (en) | 2013-12-09 | 2023-01-24 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| DK3686288T3 (da) | 2014-08-15 | 2023-05-22 | Myriad Genetics Inc | Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6923966B2 (en) * | 1999-04-08 | 2005-08-02 | Schering Corporation | Melanoma therapy |
| WO2001032145A1 (en) * | 1999-10-29 | 2001-05-10 | Board Of Regents, The University Of Texas System | Method of cancer treatment |
-
2006
- 2006-04-20 WO PCT/US2006/015528 patent/WO2006116341A1/en not_active Ceased
- 2006-04-20 AU AU2006238877A patent/AU2006238877A1/en not_active Abandoned
- 2006-04-20 CN CNA2006800130738A patent/CN101163485A/zh active Pending
- 2006-04-20 MX MX2007013056A patent/MX2007013056A/es not_active Application Discontinuation
- 2006-04-20 EP EP06751290A patent/EP1874324A1/en not_active Ceased
- 2006-04-20 BR BRPI0609939-4A patent/BRPI0609939A2/pt not_active IP Right Cessation
- 2006-04-20 US US11/408,201 patent/US20070026060A1/en not_active Abandoned
- 2006-04-20 KR KR1020077026950A patent/KR20080008367A/ko not_active Withdrawn
- 2006-04-20 CA CA002605669A patent/CA2605669A1/en not_active Abandoned
- 2006-04-20 JP JP2008507989A patent/JP2008538584A/ja not_active Withdrawn
-
2007
- 2007-10-16 IL IL186699A patent/IL186699A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006116341A1 (en) | 2006-11-02 |
| BRPI0609939A2 (pt) | 2010-05-11 |
| CA2605669A1 (en) | 2006-11-02 |
| AU2006238877A1 (en) | 2006-11-02 |
| EP1874324A1 (en) | 2008-01-09 |
| US20070026060A1 (en) | 2007-02-01 |
| JP2008538584A (ja) | 2008-10-30 |
| KR20080008367A (ko) | 2008-01-23 |
| MX2007013056A (es) | 2008-04-07 |
| CN101163485A (zh) | 2008-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2127652T3 (pl) | Sposób leczenia choroby nowotworowej wykorzystujący czynnik przeciwnowotworowy w kombinacji | |
| ZA200805760B (en) | Method for treating disseminated cancer | |
| IL197633A0 (en) | Methods for treating cancer with mva | |
| IL197914A (en) | Antibodies to ereg for cancer treatment | |
| EP2367665A4 (en) | COMPOSITION AND PROCESS FOR TREATING WOOD-BASED MATERIAL AND WOOD-BASED MATERIAL PROCESSED WITH SAID COMPOSITION | |
| GB2444389B (en) | Armor material and method for producing it | |
| IL183059A0 (en) | Cancer treatment method | |
| PL2101805T3 (pl) | Ligandy integryn do stosowania w leczeniu nowotworów | |
| IL191080A0 (en) | Method of treating breast cancer using 17-aag or 17-ag or a prodrug of either in combination with a her2 inhibitor | |
| EP1945295A4 (en) | ELECTROMAGNETIC FIELDS FOR SYSTEMIC EFFECT IN THERAPY | |
| IL238394A0 (en) | Cancer treatment method | |
| EP1868435A4 (en) | COMBINATIONS, METHODS AND COMPOSITIONS FOR TREATING CANCER | |
| EP1909854A4 (en) | METHOD FOR TREATING CANCER | |
| EP2144888A4 (en) | METHODS OF TREATING CANCER | |
| EP1755394A4 (en) | METHOD OF TREATING CANCER | |
| SI2219451T1 (sl) | Postopek za zdravljenje hematopoetskih neoplazem | |
| EP2088862A4 (en) | METHOD OF TREATING CANCER | |
| EP1855662A4 (en) | METHODS AND COMPOSITIONS FOR TREATING CANCER | |
| IL179323A0 (en) | Cancer treatment method | |
| GB0413346D0 (en) | Treating cancer | |
| IL179359A0 (en) | Cancer treatment method | |
| EP1802617A4 (en) | CANCER TREATMENT METHOD | |
| EP1951238A4 (en) | PROCESS FOR THE TREATMENT OF CHRONIC PAIN | |
| EP2307573A4 (en) | METHODS FOR SCREENING COMPOUNDS FOR TREATING CANCER | |
| ZA200804170B (en) | Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor |